肾细胞癌的代谢通路:当前治疗与未来方向
肾细胞癌(RCC)因多种代谢缺陷和扰动被视为代谢性疾病,这些缺陷源于驱动肿瘤的独特遗传学。本文通过文献检索,围绕糖酵解至线粒体功能等离散代谢通路或过程,梳理了新兴治疗策略的框架与未来干预方向。RCC细胞的代谢构成特殊的肿瘤易感环境,为新型影像应用及单药或联合靶向/免疫治疗的治疗范式提供了机会。
要点
- RCC代谢缺陷涉及糖酵解至线粒体功能等多条通路。
- 代谢缺陷影响肿瘤细胞功能及局部微环境。
- 代谢易感性为影像与治疗(单药或联合)提供新机会。
核心结论
- RCC细胞的代谢构成特殊的肿瘤易感环境,为新型影像应用及单药或联合靶向/免疫策略的治疗范式提供了机会。
研究设计与样本
- 通过文献检索,围绕离散的细胞代谢通路或过程形成主题框架,以理解新兴治疗策略并考虑未来干预。
主要发现
- 代谢缺陷涉及从糖酵解到线粒体功能的多条通路,不仅影响肿瘤细胞功能,也影响局部环境。
- 针对每条通路均识别出治疗干预的机会。
临床怎么用
- RCC代谢易感性提示可探索新型影像应用及单药或联合靶向/免疫策略的治疗范式。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Renal cell carcinoma (RCC) has become known as a metabolic disease, owing to the diverse array of metabolic defects and perturbations that occur as a result of the unique genetics that can drive these tumors. Recent attention to this feature of RCCs has fueled interest in targeting metabolism as a therapeutic strategy. METHODS: We conducted a literature search to develop themes around discrete pathways or processes of cellular metabolism, provide a framework for understanding emerging therapeutic strategies, and consider future interventions. RESULTS: Defects occur in metabolic pathways ranging from glycolysis to mitochondrial function and affect not only the tumor cell functionality, but also the local environment. We identified opportunities for therapeutic intervention associated with each pathway. CONCLUSION: The metabolism of RCC cells presents a special environment of tumor susceptibilities, with opportunities for novel imaging applications and treatment paradigms that are being tested in monotherapy or as adjuncts to targeted or immune-based strategies.
引用
- Rathmell WK, Rathmell JC, Linehan WM, et al. Metabolic Pathways in Kidney Cancer: Current Therapies and Future Directions. J Clin Oncol. 2018. PMID: 30372395. doi:10.1200/JCO.2018.79.2309
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。